Eli Lilly Prepares Billions of Weight-Loss Pills Ahead of U.S. Approval
Eli Lilly (NYSE:LLY) is gearing up for a major launch, having already produced billions of doses of its next-generation weight-loss pill in anticipation of strong global demand. The company’s CEO, Dave Ricks, shared this update during an event hosted by the Economic Club of Chicago on Monday.
“We’ve already manufactured billions of doses in preparation for the launch,” Ricks stated. “This will essentially make it the ‘GLP-1 for all,’ significantly impacting global human health.”
The weight-loss pill, orforglipron, is a once-daily GLP-1 receptor agonist designed to mimic gut hormones, helping to curb appetite and regulate blood sugar levels. Eli Lilly announced in April that orforglipron met its primary goals in a third Phase 3 trial, paving the way for global regulatory submissions. While the drug has not yet been submitted to U.S. regulators, the company plans to file for approval by the end of the year.
Eli Lilly is doubling down on its investment in the rapidly growing obesity drug market, where it faces competition from rivals like Novo Nordisk (NVO) and Viking Therapeutics (VKTX), both of which have obesity pills in development. To maintain its edge, the Indianapolis-based company is allocating $14 billion to research and development this year, focusing on launching a pipeline of innovative medicines rather than relying on a single blockbuster product.
“We’re planning to launch two more drugs in the next two years,” Ricks added. “In fact, we may launch one new therapy every year for the next five or six years. It’s about continuous innovation—like upgrading our phones—to tackle these challenges effectively.”
